Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
   
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  SWAN Knowledge Base
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  Antibodies
  Mutations
  AlzGene
  Research Models
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Expert Opinion
  Ask the Expert
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Forums: Live Discussions
What We Know, What We Don't Know
back to table  

 

What we know

What we don’t know

10.

Statins, nonsteroidal anti-inflammatories and estrogen therapy are correlated in retrospective studies with reduced risk of AD

Are these real correlations or covariants? What are the mechanisms? How better to design clinical trials to test potential preventive agents?


Comments
Comment by:  Milan Fiala
Submitted 28 May 2007 Posted 3 June 2007

Endpoints reached within 6 to 12 months of a study are essential. The amyloid-β hypothesis predicts that improved amyloid-β clearance should equate to slowing down the progression of the disease. In addition to neuroradiological tests of amyloid-β imaging (which maybe too expensive for large studies), CSF test (the ratio of amyloid-β1-42 and phospho-tau) is widely used in Europe and is economical. We have observed (Zhang et al., 2006) that immune testing of peripheral blood macrophages might be also helpful. The design of future studies should include both CSF and immune blood tests. The drugs likely work only in earlier stages of the disease.

References:
Zhang L, Fiala M, Cashman J, Sayre J, Espinosa A, Mahanian M, Zaghi J, Badmaev V, Graves MC, Bernard G, Rosenthal M. Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients. J Alzheimers Dis. 2006 Sep;10(1):1-7. Abstract

View all comments by Milan Fiala

Comment by:  Touqeer Ahmed
Submitted 14 April 2008 Posted 22 April 2008

Amyloid-beta (Aβ) levels in the cerebrospinal fluid and interstitial fluid are controlled by complicated and partially known processes of production and clearance. Increases in Aβ levels result in nucleation and fibrillar formation of peptides, hence, plaque deposition. Zhang et al. (2006) showed that curcuminoids (a mixture of natural compounds) enhance uptake of Aβ; this may result in decreased Aβ levels, highlighting the usefulness of curcuminoids along with opening new areas for investigation.

In addition, a recent report by Cirrito et al. (2008) highlighted that the endocytosis of amyloid precursor protein into endosomes results in processing and release of Aβ into the interstitial space. Similarly, these authors also explained that, with increased synaptic activity, there is an increase in the endocytosis and in turn more Aβ release. Curcuminoids may command attention. They could be studied for their effect on the overall release of Aβ, as we are beginning to understand their role in clearance. These above-mentioned studies...  Read more

View all comments by Touqeer Ahmed

  Submit a Comment

 
Cast your vote and/or make a comment on this page. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
Print this page
Email this page
Alzforum News
Text size
Share & Bookmark
Polls
       
How are you doing in the current funding climate?
 
Fine
 
OK, but the effort to write grants is hurting my research
 
Still OK, but am afraid for the future
 
Not OK, may have to leave the field
 
Terrible, have left the AD field
 
 
 
 
 
Archived Polls
 
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2008 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad